Recombinant human thrombopoietin

重组人血小板生成素

Report date: 2026/03/13 20:02:36

Base Information

Drug NameRecombinant human thrombopoietin
Drug Alias NamerHuTPO (3SBio)特比奥Tpiao特比澳Tebiao +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsRadiation sicknessNeutropeniaMyelodysplastic-Myeloproliferative Diseases +[14] 
Global Approved IndicationsThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic
Approved Indications in ChinaThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic
Original Approved Country/TerritoryMainland China
Original Approved Date2005/03/10
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenyang Sunshine Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Jiao Tong University School of MedicineShanghai University Of Traditional Chinese MedicineShenyang Sunshine Pharmaceutical Co Ltd
Inactive CompaniesShandong UniversityNational Cancer InstituteNorthwestern University
Active IndicationsRadiation sicknessThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic +[4] 
Inactive IndicationsNeutropeniaMyelodysplastic-Myeloproliferative DiseasesLiver Cirrhosis +[10] 

Other Information

ATC CodeL03AA
Related LinksWikipedia